Advaxis
is a New Jersey-based biotechnology company that develops and commercializes immunotherapies for the treatment of cancer... Read moreAdvaxis
is a New Jersey-based biotechnology company that develops and commercializes immunotherapies for the treatment of cancer... Read more
News
Aug 10, 2023
Owler
Advaxis, Inc.: Advaxis's revenue changed from $-204K in Mar 2023 to $-233K in Jun 2023
Mar 18, 2023
Owler
Advaxis, Inc.: Advaxis's employee count changed from 14 in Oct 2021 to 15 in Dec 2022
Jan 30, 2023
MarketScreener
Advaxis: Advaxis : Certificate of Incorporation/Bylaws - Form 8-K
Jan 20, 2023
NJBIZ
Advaxis: Advaxis completes merger to become Ayala Pharmaceuticals
Jan 14, 2023
Pharmabiz
Advaxis: Advaxis updates on phase 1 clinical trial of ADXS504 to treat early prostate cancer
Oct 26, 2022
Global Legal Chronicle
Advaxis: Advaxis' Merger with Ayala Pharmaceuticals
Sep 13, 2022
FirstWord Pharma
Advaxis: Advaxis Reports Third Quarter Ended July 31, 2022 Financial Results and Provides a Business Update
Sep 13, 2022
Markets Insider
Advaxis: Advaxis GAAP EPS of -$3.83
Jun 29, 2022
centralcharts
Press Release: Advaxis : Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
Jun 28, 2022
FirstWord Pharma
Advaxis: Immunotherapy nano-cap Advaxis withdraws $9 million Nasdaq uplisting
Advaxis Competitors
1
2
3
4
5
6
7
8
9
10